Heplisav-b Injection, Solution
NDC Package 83703-048-05
Package Information
Heplisav-b (hepatitis b vaccine (recombinant) adjuvanted) injection is classified as a
- actively acquired immunity - [pe] (physiologic effect)
- hepatitis b vaccines - [cs]
- inactivated hepatitis b virus vaccine - [epc] (established pharmacologic class)
- vaccines administered via intramuscular route. This formulation utilizes a injection, solution delivery system. Marketed by Bamboo Us Bidco Llc, this product is identified by NDC 83703-048 and is authorized under FDA application BLA125428.
Identification & Billing
- RxCUI: 2050057 - hepatitis B surface antigen vaccine 20 MCG in 0.5 ML Prefilled Syringe
- RxCUI: 2050057 - 0.5 ML hepatitis B surface antigen vaccine 0.04 MG/ML Prefilled Syringe
- RxCUI: 2050057 - hepatitis B surface antigen vaccine 0.04 MG/ML per 0.5 ML Prefilled Syringe
- RxCUI: 2050059 - HEPLISAV-B 20 MCG in 0.5 ML Prefilled Syringe
- RxCUI: 2050059 - 0.5 ML hepatitis B surface antigen vaccine 0.04 MG/ML Prefilled Syringe [Heplisav-B]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 83703 - Bamboo Us Bidco Llc
- 83703-048 - Heplisav-b
- 83703-048-05 - 5 SYRINGE in 1 CARTON / .5 mL in 1 SYRINGE (83703-048-01)
- 83703-048 - Heplisav-b
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 83703-048-05 identifies a specific commercial package of 5 syringe in 1 carton / .5 ml in 1 syringe (83703-048-01) of Heplisav-b, a vaccine label labeled by Bamboo Us Bidco Llc. This injection, solution is formulated for intramuscular use and contains hepatitis b virus subtype adw hbsag surface protein antigen as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Bamboo Us Bidco Llc on January 01, 2018. The current certification is valid through December 31, 2027.
How is this Bamboo Us Bidco Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 83703004805. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.